Zacks Investment Research downgraded shares of Genmab As (OTCMKTS:GNMSF) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. cut shares of Genmab As from an overweight rating to a neutral rating in a research note on Friday, October 6th.

Shares of Genmab As (OTCMKTS GNMSF) remained flat at $$186.75 during midday trading on Tuesday. 126 shares of the stock were exchanged, compared to its average volume of 1,955. The stock has a market capitalization of $11,426.42, a price-to-earnings ratio of 64.62 and a beta of 0.96. Genmab As has a twelve month low of $163.00 and a twelve month high of $239.75.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at

About Genmab As

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Get a free copy of the Zacks research report on Genmab As (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with Analyst Ratings Network's FREE daily email newsletter.